<DOC>
	<DOCNO>NCT02532686</DOCNO>
	<brief_summary>Pharmacotherapy schizophrenia limitation residual positive negative symptom , cognitive deficit intolerable side effect . Refractory schizophrenia still difficult clinical issue present . According N-methyl-D-aspartate ( NMDA ) hypothesis , adjuvant NMDA-enhancing agent may therapeutic benefit . DAAOI-2 , D-amino acid oxidase ( DAAO ) inhibitor , NMDA-enhancing agent . The aim project examine effectiveness safety DAAOI-2 add-on treatment treatment-resistant schizophrenia patient randomize , double-blind , placebo-controlled trial .</brief_summary>
	<brief_title>DAAOI-2 add-on Treatment Treatment-resistant Schizophrenia</brief_title>
	<detailed_description>Pharmacotherapy schizophrenia limitation residual positive negative symptom , cognitive deficit intolerable side effect . Refractory schizophrenia still difficult clinical issue present . According N-methyl-D-aspartate ( NMDA ) hypothesis , many clinical trial NMDA-enhancing agent study . Adjuvant NMDA-enhancing agent , include glycine , D-amino acid D-serine , sarcosine ( glycine transporter I inhibitor ) , reveal beneficial limited efficacy positive negative symptom . The aim project examine effectiveness safety DAAOI-2 add-on treatment treatment resistant schizophrenia patient randomize , double-blind , placebo - control trial .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Fulfill DSMIV criterion schizophrenia Treatment resistant : No satisfactory response least two kind antipsychotic Remain symptomatic without clinically significant fluctuation antipsychotic dos unchanged least 3 month Have minimum baseline total score 70 Positive Negative Syndrome Scale ( PANSS ) Agree participate study provide informed consent Meet DSMIV criterion substance ( include alcohol ) abuse dependence Meet DSMIV criterion mental retardation Serious medical neurological illness Pregnancy lactation Inability follow protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Treatment resistant</keyword>
	<keyword>DAAOI</keyword>
	<keyword>NMDA</keyword>
</DOC>